vFT011, vFT012 | Future&Tech

R&D

You can scroll left and right to view the full content.

Pipeline	Development Projects	Target diseases
vFT001	FT005-002 (MyoLac II)	Industrial animal improvements
vFT005	FT005-002 (MyoLac II)	Industrial animal improvements
vFT011	FT005-005 (Lobster)	Melanoma, Lymphoma
vFT012	FT005-004 (Crab)	Osteosarcoma, Mast cell tumors, Mammary tumors

vFT011(Lobster), vFT012(Crab) projects

Incidence of cancer in pet dogs: 25-30% (over 50% in dogs over 10 years old)

Mostly commonly diagnosed cancer: lymphoma, mammary tumor, skin cancer, osteosarcoma

1. Diseases in scope for vFT011, B7-H3 targeted active immunotherapy

Osteosarcoma: high level of B7-H3 expression is observed in canine osteosarcoma. Treatment inhibits cancer invasion and immune evasion
Mast cell tumors: a common skin cancer in dogs. Treatment reduces immune evasion
Splenic hemangiosarcoma: A frequently diagnosed vascular sarcoma in dogs. Treatment lowers tumor aggressiveness
Mammary tumors: Treatment weakens immune suppression mechanisms in canine mannary tumors

2. Diseases in scope for vFT012, B7-H1 targeted active immunotherapy

Lymphoma: tumor commonly found in dogs and cats. Treatment lowers immune evasion
Melanoma: Frequently observed in the oral cavity and around the nail in dogs. Treatment lowers immune evasion
Osteosarcoma: a common bone cancer in dogs. Treatment reduces immune evasion, treatment resistance, tumor aggression and metastasis
Transitional cell carcinoma (TCC): Common in dogs. Treatment inhibits immune evasion and slows tumor progression
Mammary tumor: common in female dogs. Treatment suppresses immune evasion and reduce tumor malignancy

Pet cancer immunotherapy

Pet cancer immunotherapy - Mechanism of action, Development progress,Market size,Target diseases and competitors
Mechanism of action	Neutralizes immune checkpoint ligands B7-H1 and B7-H3, enabling cototoxic cells to effectively eliminate cancer cells
Development progress	Mass expression of B7-H1 or B7-H3 on the surface of lactic acid bacteria Formation of anti-B7H1 and anti-B7H3 antibodies in normal mice Evaluating administration modes, dosage, and formulas with live/inactivated bacteria
Market size	USD 6.12 billion as of 2022 (Approximately KRW 8.26 trillion. FX: 1,350 KRW/USD) CAGR 11.3% from 2023 - 2030 North America takes up approximately 48% of the global market Asia-Pacific market shows a rapid growth: CAGR 33% Reference: Virtue Market Research, Global Immunotherapy-based Pet Cancer Therapeutics Market Research Report
Target diseases and competitors	Lymphoma, Mast Cell Cancer, Melanoma, Mammary, Squamous Cell Cancer AB Science, Boehringer Ingelheim International GmbH, ELIAS Animal Health LLC, Karyopharm Therapeutics, Pfizer Inc., Virbac, Zoetis Inc.